<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18150</article-id><article-id pub-id-type="doi">10.15690/vramn18150</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ONCOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ОНКОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of risk factors for progression and prognosis of survival in HPV-associated cervical cancer: a retrospective study</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ факторов риска прогрессирования и прогноза выживаемости при ВПЧ-ассоциированном раке шейки матки: ретроспективное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-9229-732X</contrib-id><contrib-id contrib-id-type="spin">3953-5075</contrib-id><name-alternatives><name xml:lang="en"><surname>Semikoz</surname><given-names>Natalia G.</given-names></name><name xml:lang="ru"><surname>Семикоз</surname><given-names>Наталья Григорьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Corresponding Member of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН</p></bio><email>nataligrsemikoz@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-7781-6833</contrib-id><contrib-id contrib-id-type="spin">4136-3313</contrib-id><name-alternatives><name xml:lang="en"><surname>Rogalev</surname><given-names>Artem V.</given-names></name><name xml:lang="ru"><surname>Рогалев</surname><given-names>Артем Валериевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>dr.onc.art@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7987-4091</contrib-id><contrib-id contrib-id-type="spin">3565-8254</contrib-id><name-alternatives><name xml:lang="en"><surname>Kishenya</surname><given-names>Maria S.</given-names></name><name xml:lang="ru"><surname>Кишеня</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor, Senior Research</p></bio><bio xml:lang="ru"><p>к.м.н., доцент, с.н.с.</p></bio><email>maria.kishenya@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-5649-403X</contrib-id><contrib-id contrib-id-type="spin">8155-7161</contrib-id><name-alternatives><name xml:lang="en"><surname>Pishchulina</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>Пищулина</surname><given-names>Светлана Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Senior Research Associate</p></bio><bio xml:lang="ru"><p>к.м.н., с.н.с.</p></bio><email>svetlana-pishulina@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Oncological Center named after Professor G.V. Bondar</institution></aff><aff><institution xml:lang="ru">Республиканский онкологический центр имени профессора Г.В. Бондаря</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">V.K. Gusak Institute of Urgent and Reconstructive Surgery</institution></aff><aff><institution xml:lang="ru">Институт неотложной и восстановительной хирургии им. В.К. Гусака</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Donetsk State Medical University name after M. Gorky</institution></aff><aff><institution xml:lang="ru">Донецкий государственный медицинский университет имени М. Горького</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-06-19" publication-format="electronic"><day>19</day><month>06</month><year>2026</year></pub-date><volume>81</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>107</fpage><lpage>115</lpage><history><date date-type="received" iso-8601-date="2025-11-25"><day>25</day><month>11</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-04-19"><day>19</day><month>04</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Издательство "Педиатръ"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-12-19"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/18150">https://vestnikramn.spr-journal.ru/jour/article/view/18150</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Among the most significant risk factors for the development of cervical cancer is human papillomavirus (HPV) infection. Stratifying patients by risk of progression is essential for a differentiated approach to cervical cancer treatment. There are currently insufficient studies examining the relationship between HPV-associated cervical cancer and risk factors for progression to assess survival prognosis. <bold>Aims</bold> — to assess the role of HPV infection in the formation of postoperative risk factors for progression and survival prognosis in patients with cervical cancer. <bold>Methods.</bold> A retrospective study was conducted involving 194 patients with stage I–II cervical cancer (TNM) after radical hysterectomy according to Wertheim with a course of radiation therapy at the Republican Oncology Center named after prof. G.V. Bondar of the Ministry of Health of the Donetsk People’s Republic from 2014 to 2022. PCR testing was used to form groups with HPV-positive and HPV-negative status. A comparative analysis of differences in the frequencies of data between the groups, such as age, cervical cancer stage, size, histological type and degree of differentiation of the tumor, LVSI, and depth of stromal invasion (DSI), was performed using the χ<sup>2</sup> criterion. The association of HPV status with overall survival (OS) and relapse-free survival (RFS) was estimated using the Kaplan-Meier method. To study the influence of risk factors on survival rates in the HPV-positive group, univariate and multivariate analysis of the Cox proportional hazards regression model was used. <bold>Results.</bold> HPV-positive status was determined in 118 patients (60.82%), HPV-negative status in 76 (39.18%). In HPV infection, the number of patients with moderate tumor differentiation prevailed (p = 0.003). LVSI (p = 0.045), with DSI more than 1/3 of the cervical myometrial thickness (p = 0.006), with a tumor size of &gt; 4 cm (p = 0.027). The 5-year OS rates with HPV-positive status and HPV-negative status were 92.37 and 98.68% (p = 0.027), 5-year RFS — 83.05 and 98.68% (p = 0.0001). In multivariate analysis, the significant factor for OS was the histological type of adenocarcinoma (p = 0.008), for RFS – adenocarcinoma (p = 0.031) and the degree of moderate differentiation (p = 0.013) and GSI &gt; 1/3 of the myometrial wall (p = 0.013). <bold>Conclusions. </bold>An association between HPV infection in cervical cancer and decreased OS and RFS has been established. Significant prognostic factors associated with an increased risk of recurrence in cervical cancer included the histological type of adenocarcinoma, the degree of moderate differentiation, and a GSI greater than one-third of the cervical wall thickness. The results of clinical and pathological parameters in cervical cancer are important for risk stratification and treatment strategies.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Одним из наиболее значимых факторов риска развития рака шейки матки (РШМ) является инфицирование вирусом папилломы человека (ВПЧ). Для дифференцированного подхода в лечении РШМ важна стратификация пациенток по группам риска прогрессирования. Исследований связи ВПЧ-ассоциированного РШМ и факторов риска прогрессирования для оценки прогноза выживаемости в настоящее время проведено недостаточно. <bold>Цель исследования</bold> — оценить роль ВПЧ-инфицирования в формировании после-операционных факторов риска прогрессирования и прогноза выживаемости у пациенток с РШМ. <bold>Методы. </bold>Проведено ретроспективное исследование на основании данных медицинской документации 194 пациенток с РШМ I–II стадии (TNM) после радикальной гистер-эктомии по Вертгейму с курсом лучевой терапии на базе Республиканского онкологического центра им. проф. Г.В. Бондаря Минздрава ДНР с 2014 по 2022 г. При ПЦР-тестировании сформированы группы с ВПЧ-позитивным и ВПЧ-негативным статусом. Сравнительный анализ различий частот данных между группами, таких как возраст, стадия РШМ, размер, гистологический тип и степень дифференцировки опухоли, инвазия лимфоваскулярного пространства (ЛВСИ), глубина стромальной инвазии (ГСИ), проводили с помощью критерия χ<sup>2</sup>. Связь ВПЧ-статуса с общей и безрецидивной выживаемостью оценивали методом Каплана–Мейера. Для изучения влияния факторов риска на показатели выживаемости в группе с ВПЧ-позитивным статусом использовали одно- и многофакторный анализ регрессионной модели пропорциональных рисков Кокса. <bold>Результаты. </bold>ВПЧ-позитивный статус определен у 118 (60,82%) пациенток, ВПЧ-негативный — у 76 (39,18%). При ВПЧ-инфицировании преобладало число пациенток с умеренной дифференцировкой опухоли (p = 0,003), ЛВСИ (p = 0,045), с ГСИ более 1/3 толщины миометрия шейки матки (p = 0,006), с размером опухоли &gt; 4 см (p = 0,027). Показатели 5-летней общей выживаемости с ВПЧ-позитивным статусом и ВПЧ-негативным статусом составили соответственно 92,37 и 98,68% (р = 0,027), 5-летней безрецидивной выживаемости — 83,05 и 98,68% (р = 0,0001). При многофакторном анализе значимым фактором для общей выживаемости являлся гистологический тип аденокарцинома (p = 0,008), для безрецидивной выживаемости — аденокарцинома (p = 0,031) и степень умеренной дифференцировки (p = 0,013) и ГСИ &gt; 1/3 стенки миометрия (p = 0,013). <bold>Заключение. </bold>Установлена связь ВПЧ-инфицирования при РШМ со снижением общей и безрецидивной выживаемости. Значимыми прогностическими факторами, связанными с повышенным риском рецидива при РШМ, являлись гистологический тип аденокарциномы, степень умеренной дифференцировки и ГСИ более 1/3 толщины стенки шейки матки. Результаты исследования клинико-патологических параметров при РШМ имеют значение для стратификации риска и стратегии лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cervical cancer</kwd><kwd>lymphovascular invasion</kwd><kwd>depth of stromal invasion</kwd><kwd>tumor diameter</kwd><kwd>survival analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак шейки матки</kwd><kwd>лимфоваскулярная инвазия</kwd><kwd>глубина стромальной инвазии</kwd><kwd>диаметр опухоли</kwd><kwd>анализ выживаемости</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: https://doi.org/10.3322/caac.21834</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Каприн А.Д., Старинский В.В., Шахзадова А.О., и др. Злокачественные новообразования в России в 2022 году (заболеваемость и смертность): монография. — М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. — 275 с. [Kaprin AD, Starinsky VV, Shakhzadova AO, et al. Malignant tumors in Russiain 2022 (morbidity and mortality). Мonograph. Moscow: P.A. Herzen Moscow State Medical Research Institut — branch of the FSBI NMITs of Radiology of the Ministry of Health of Russia, 2023. 275 p. (In Russ.)]</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cibula D, Pötter R, Planchamp F. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Int J Gynecol Cancer. 2018;28(4):641–655. doi: https://doi.org/10.1097/IGC.0000000000001216</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cohen PA, Jhingran A, Oaknin A. Cervical cancer. Lancet. 2019;393(10167):169–182. doi: https://doi.org/10.1016/S0140-6736(18)32470-X</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kim Н, Park W, Kim YS, et al. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. J Gynecol. Oncol. 2020;31(3):e35. doi: https://doi.org/10.3802/jgo.2020.31.e35</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ma GF, Lin GL, Wang ST, et al. Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy. BMC Womens Health. 2024;24(1):81. doi: https://doi.org/10.1186/s12905-023-02853-8</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Margolis B, Cagle-Colon K, Chen L, et al. Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer. Int J Gynecol Cancer. 2020;30(6):735–743. doi: https://doi.org/10.1136/ijgc-2019-000849</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hou W, Ma Y, Sun S, et al. Predictive factors for postoperative recurrence in early cervical cancer patients: a meta-analysis. Front Surg. 2024;12:1588558. doi: https://doi.org/10.3389/fsurg.2025.1588558</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Кравцова Е.А., Цыганов М.М., Литвяков Н.В., и др. ВПЧ-ассоциированный рак шейки матки: современное состояние и перспективы // Acta biomedical scientifica. — 2023. — Т. 8. — № 3. — С. 42–54. [Kravcova EA, Cyganov MM, Litvyakov NV, et al. HPV-associated cervical cancer: Current status and prospects. Acta biomedical scientifica. 2023;8(3):42–54. (In Russ.)] doi: https://doi.org/10.29413/ABS.2023-8.3.4</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020;471:88–102. doi: https://doi.org/10.1016/j.canlet. 2019.11.039</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Giorgi Rossi P, Carozzi F, Ronco G, et al. p16/ki67 and E6/ E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. J Natl Cancer Inst. 2021;113(3):292–300. doi: https://doi.org/10.1093/jnci/djaa105</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018;9:2896. doi: https://doi.org/10.3389/fmicb.2018.02896</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhang S, Xu H, Zhang L, et al. Cervical cancer: Epidemiology, risk factors andscreening. Chin J Cancer Res. 2020;32(6):720–728. doi: https://doi.org/10.21147/j.issn.1000-9604.2020.06.05</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sun X, He L, Wang S. Risk factors for pelvic lymph node metastasis in cervical cancer: a retrospective analysis of 186 patients. Front Oncol. 2025;15:1525946. doi: https://doi.org/10.3389/fonc.2025.1525946</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Хохлова С.В., Кравец О.А., Морхов К.Ю, и др. Рак шейки матки. Практические рекомендации RUSSCO, часть 1.2 // Злокачественные опухоли. — 2024. — Т. 14. — № 3s2. — С. 136–164. [Hokhlova SV, Kravec OA, Morkhov KYu, i dr. Rak shejki matki. Prakticheskie rekomendacii RUSSCO, chast’ 1.2. Zlokachestvennye opukholi. 2024;14(3s2):136–164. (In Russ.)] doi: https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-05</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhou Y, Wang W, Tang J, et al. Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery. BMC Cancer. 2024;24(1):548. doi: https://doi.org/10.1186/s12885-024-12284-9</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nishimura H, Amano T, Yoneoka Y, et al. Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer. J Gynecol Oncol. 2024;36(1):e2. doi: https://doi.org/10.3802/jgo.2025.36.e2</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kim SM, Kwon IJ, Myoung H, et al. Identification of human papillomavirus (HPV) subtype in oral cancer patients through microarray technology. Eur Arch Otorhinolaryngol. 2018;275(2):535–543. doi: https://doi.org/10.1007/s00405-017-4828-9</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Simms KT, Hanley SJB, Smith MA, et al. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):е223–е234. doi: https://doi.org/10.1016/S2468-2667(20)30010-4</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dzinamarira T, Moyo E, Dzobo M, et al. Cervicalcancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services. Int J Gynecol Cancer. 2023;33(4):592–597. doi: https://doi.org/10.1136/ijgc-2022-003957</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Chen X, Zhang P, Chen S, et al. Better or Worse? The independent рrognostic role of HPV-16 or HPV-18 рositivity in рatients with сervical сancer: A meta-аnalysis and systematic review. Front Oncol. 2020;10:1733. doi: https://doi.org/10.3389/fonc.2020.01733</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bae BK, Cho WK, Kim BG, et al. Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification. Int J Gynecol Cancer. 2022;32(12):1524–1530. doi: https://doi.org/10.1136/ijgc-2022-003971</mixed-citation></ref></ref-list></back></article>
